You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Anoro Ellipta Scientific Data

Go to  Close  Top

Vs Tio

Anoro is a once-daily combination of two different yet complementary bronchodilators delivered in the Ellipta inhaler:

Anoro provides a clinically meaningful difference to patient's breathing, with 112ml greater improvement in trough FEV 1vs. tiotropium in the largest comparative study (ZEP117115).

Primary endpoint: Least squares (LS) mean changes in trough FEV 1from baseline at Day 169.

The lung function benefits for Anoro Ellipta versus tiotropium translate into benefits in terms of patient reported outcomes like rescue medication usage, and health-related quality of life (SGRQ score).


Anoro reduces rescue medication use and improves SGRQ compared with tiotropium in the largest comparative study (ZEP117115) 2
 

Click here to read more on the indication of Anoro

References:

  1. Anoro Ellipta Hong Kong Prescribing Information 2017.
  2. Maleki-Yazdi M et al. Respir Med 2014; 108:1752–1760.

Trade marks are owned by or licensed to the GSK group of companies and ©2017 GSK group of companies or its licensor. Anoro and Relvar are developed in collaboration with Innoviva.